RCT Tildrakizumab (IL23i) in Psoriatic Arthritis Beat PLBO for ACR20 (NNT~4), ACR50 (NNT~4), and pt global (NNT~3 for 50% improvement) Very well tolerated (NNH>50, any adverse event) Exciting new tx! Need comparison RCT vs TNF/IL17i @RheumNow #acrbest #ACR19 Abst#1821 https://t.co/QFQEA8L3sY